AstraZeneca’s new UK lung cancer drug is hailed as a ‘game changer’ that can HALF the risk of death By Kate Pickles Updated: 5:43 PM EDT, June 4, 2023 Research has shown that a ‘breakthrough’ British drug can halve the risk of dying from lung cancer. The groundbreaking study found that patients who received osimertinib after surgery were 51 percent more likely to be alive five years later than those given a dummy pill. The daily tablets target non-small cell lung cancer (NSCLC) cancers among people who have a specific…
Read More